

Title: SARS-CoV-2 seroprevalence and gender-related haematological features in asymptomatic blood donors

Running Title: SARS-CoV-2 seroprevalence and gender-related haematological features

M Carmen Martín ^a, M Isabel González ^a, Nuria Holgado ^a, Ana I Jimenez ^a, Nuria Ortega ^a, Isabel Page ^a, Alba Parrado ^a, María Pérez ^a, Lydia Blanco-Peris ^a, ^a
Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos
s/n, 47007 Valladolid, Spain

Corresponding author: M Carmen Martín; cmartinalo@saludcastillayleon.es;
Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos
s/n, 47007 Valladolid, Spain

SARS-CoV-2 seroprevalence and gender-related hematological features in asymptomatic blood donors

Abstract

Background and objectives: COVID-19 can either cause death or go unnoticed but antibodies will remain protecting us of SARS-CoV-2 reinfection for an uncertain time and to an uncertain extent. Our aim was to describe seroprevalence evolution from summer 2019 to autumn 2020 in Spain and to describe its relationship with age, blood group and haematological parameters.

Materials and methods: Sera and plasma from historical donation archives excluding convalescent were randomized and a total of 12,313 donations tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9% males, average age 46+/-13. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings.

Results: A seroprevalence of 6.7% in blood donors was found by the end of the first wave. No differences by sex, age or blood group were found regarding antibodies. Leukocyte count ($p=0.026$), haematocrit ($p<0.001$) and haemoglobin ($p<0.001$) were lower in positive donations than in negative ones. Sex differences were present in neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.

Conclusions: Seroprevalence due to asymptomatic cases would resemble that of global population. Sex and age would not affect COVID-

19 susceptibility but its severity. Gender differences related to COVID-19 in leukocytes, haemoglobin and haematocrit would be present in asymptomatic individuals. Further studies are needed to confirm these gender differences as they can help better understand the immune response to COVID-19, its pathogenesis and prognosis.

Keywords: COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-

2

1 **Introduction**

2 An unknown amount of individuals infected with SARS-CoV-2 present no
3 symptoms or a mild disease that can go unnoticed. This make it difficult to
4 estimate infection rates, prevalence, calculating absolute risks of COVID-
5 19 or predicting the spread of the virus and the growth of herd immunity.
6 [1]. Immunization either due to infection or to vaccination leads specific T
7 cell responses and production of antibodies against SARS-CoV-2 usually
8 peaking 8–15 days after infection [2]. Antibodies that neutralize the virus
9 are the primary protection against COVID-19.

10 Antibody assays are quite different: they either detect antibodies against
11 different viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin
12 classes: IgG, IgM, IgA or their combinations. It should be noticed that
13 every approved vaccine in Europe to date (May 2020) enhances anti-S
14 responses, whereas an infection leads to a multi specific response to
15 SARS-CoV2 antigens. To make it even messier, many factors can
16 influence test performance, including cross-reactivity with other
17 coronaviruses or platform (laboratory-based vs point-of-care, lateral flow).

18 Chemiluminiscence assays have suitable performances regarding both
19 sensibility and sensitivity while correlation to neutralizing antibodies would
20 be around 0.7 [3].

21 Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has
22 accumulated nearly 225.000 COVID-19 confirmed cases
23 (<https:// analisis.datosabiertos.jcyl.es/>), with an overall case-fatality rate of
24 3.01 to date. Our institution, Centro de Hemoterapia de Castilla y León
25 keeps within its Biobank plasma samples from every single donation along
26 the last ten years, that makes up around one million samples. Any
27 demographic data such as sex or age and laboratory parameters (blood
28 counts, blood group, haemoglobin, etc....) is as well kept in a database
29 (Hemasoft, eDelphyn).

30 Blood donor-based serosurveillance is a powerful and cost-effective
31 strategy to monitor infectious diseases. There are quite a lot of infections
32 for which routine donor screening is undoubtedly useful, including human
33 immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus
34 (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV)
35 [1], babesiosis or Crimea-Congo fever. The use of blood donor samples
36 means we are sampling mainly asymptomatic and recovered cases of
37 COVID-19 (donation is allowed after 28 days following COVID-19
38 resolution of symptoms).

39 Seroprevalence surveys are then needed to monitor coronavirus
40 pandemic, both before and after vaccination strategies [4]. Reported
41 COVID-19 cases do not represent the full SARS-CoV-2 disease burden

42 due to low detection rates, especially at the beginning of pandemics. Case
43 reports are dependent on patients' seeking health care, massive local
44 screenings or regional tracking activities. Analysis of data from
45 seroprevalence and serosurveillance is a common strategy for estimating
46 underreporting and real disease burden. Time between infection and
47 antibody development or antibody waning must be considered to
48 understand seroprevalence surveys avoiding biases. Serological surveys
49 with a random sampling design of the general population are difficult to
50 perform in a pandemic, but they would yield a seroprevalence estimate
51 least likely to be affected by selection bias. Blood donors are a quite
52 representative subset of general population aged 18-65 and our historical
53 plasma collection was big enough to perform a systematic time-layered
54 randomization.

55 Heterogeneity of susceptibility and transmission are hard to evaluate [5]. A
56 portion of the population is not susceptible to infection from the first
57 pathogen contact. Some of them may have pre-existing immunity via
58 cross-reactivity or particular host factors such as mucosal immunity or
59 trained innate immunity protection (as it has been reported to be conferred
60 by DTP or BCG vaccination)[6]. There is as well a proportion of
61 seronegative individuals that will develop immunity by T cell mediated
62 responses without exhibiting an antibody response [7].

63 Our starting hypothesis was the existence of a certain number of
64 asymptomatic carriers of the SARS-CoV-2 virus that would develop
65 antibodies against it [7] and subsequently contribute to herd immunity.

66 Those asymptomatic cases were unnoticeable before SARS-CoV-2 testing
67 began and might have been circulating from an unknown moment. Early
68 cases have been described in France [8], arising the question of whether
69 the pathogen could have been circulating before the official recording of
70 the first cases.

71 The main aim of this study was to determine which percentage of the
72 population has had contact with SARS-CoV-2 at different times and had
73 therefore developed antibodies against it. A secondary goal was to
74 describe related haematological features of seropositive donors and
75 establish whether sex, age, blood group or haematological abnormalities
76 could be related to past COVID-19 infection.

77 Knowledge of COVID-19 epidemiological and haematological features
78 should help make a good forecast of resources for possible future
79 outbreaks or vaccination strategies, and would facilitate decisions in the
80 social sphere by a more reliable estimate of the percentage of immunized
81 individuals.

82 **MATERIAL and METHODS**

83 Seroprevalence and haematological features were studied blood, plasma
84 (excluding convalescent) and platelet donations from July 2019 to October
85 2020. The 101,183 donations from 70,181 donors collected since
86 19/07/2019 (week -24) to 19/10/2020 (week 43) were systematically
87 randomized to select a minimum of 127 donations per week, calculated on
88 the basis of the total number of donations and the length of the analysis
89 period. Then, 1650 convalescent plasma donation were excluded. A total

90 of 12,718 samples of 12,313 donations from 11,444 donors over 18 years
91 old were included.

92 All haematological and demographic data were extracted from our
93 electronic database eDelphyn (Hemasoft). Variables analysed included
94 age, sex, blood group, and laboratory data: leukocyte (WBC), neutrophil,
95 lymphocyte, platelet, monocyte, eosinophil and basophil counts
96 (cells*10³/μL) and their percentages, serum immunoglobulins IgG, IgA and
97 IgM (mg/dL), haemoglobin (Hb), and haematocrit (HCT) were analysed as
98 well.

99 An automated chemiluminescence double-antigen sandwich immunoassay
100 for the in vitro semi quantitative detection of total antibodies to SARS-CoV-
101 2 in human plasma and serum frozen samples. The target antigen of this
102 immunoassay is a recombinant nucleocapsid (N) protein. Elecsys® Anti-
103 SARS-CoV-2 (Roche, Basel, Switzerland) detects antibodies correlating
104 with virus-neutralizing ones and is therefore useful to help characterize the
105 immune reaction to SARS-CoV-2 [9, 10]. Immunoassay was validated by
106 our serology lab by testing of 6 pairs of samples (plasma EDTA and
107 serum) from diagnosed PCR-positive, symptomatic cases infected by mid-
108 April, that were previously reported positive by the Spanish National
109 Microbiology Centre, and checked to be as well positive for IgG
110 (Chemiluminescence, N protein, Abbott Alinity S, Chicago USA) and IgA
111 (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2.
112 Another set of ten prepandemic samples, therefore supposed to be
113 negative, were equally analysed. 405 donations were analysed both in
114 serum and plasma to verify interchangeability. A 100% concordance was

115 yielded by all these validation assays. The cut-off was that recommended
116 by manufacturer (OD>1 to report reactivity). Researchers performing anti
117 SARS-CoV-2 analyses were blind to the condition of COVID-19
118 convalescence and to any other characteristic of the donors or to the
119 donation dates.

120 Demographic and clinical characteristics of patients are expressed as their
121 mean, median, standard deviation (SD) and interquartile range (IQR) for
122 continuous variables and frequency distributions are reported for
123 categorical variables. Age was analysed both as continuous and
124 categorical variable; in the latter case was recoded into 4 groups: <30, 30-
125 45, 45-60 and 60-75 years old.

126 Kolmogorov-Smirnov test was performed on each continuous variable to
127 contrast normality. Only IgG and IgM serum levels followed normal
128 distributions, therefore non-parametric Mann-Whitney U test was
129 performed. To contrast independence of categorical variables, Pearson's
130 Chi-square and Fisher's exact test were carried out. All tests were
131 calculated with a confidence level of 0.05.

132 The Biobank is included in the National Registry of Biobanks (RD17 /
133 16/2011) with the number B.0000264. The institution holds an ISO 9001:
134 2015 certification endorsing our granting of safety and traceability of any
135 human biological sample we distribute, always behaving Spanish and
136 European rules on human samples and data protection management.

137 This study was conducted according with national regulations, institutional
138 policies and in the tenets of the Helsinki Declaration. It was approved by

139 the Valladolid Health Area Drug Research Ethics Committee, on June
140 11th, 2020 with the reference number BIO-2020-93. Included donors
141 consented to participate in Biobank research activities. The privacy rights
142 were always observed.

143 **Results**

144 The 101,183 donations from 70,181 donors along 67 weeks (July 2019 to
145 October 2020) were systematically randomized, discarding convalescent
146 plasma ones and a total of 12,313 donations (either whole blood,
147 plasmapheresis or platelet apheresis) were tested for total anti SARS-
148 CoV-2 antibodies. Donors were 11,444 individuals, 60.91% males, aged
149 18-75, average 46+/-13, 45.8% A, 40.3% O, 10.56% B, 3.31% AB.
150 Baseline characteristics descriptive analyses are summarized in Table 1.
151 Immunoglobulin results are usually performed only once a year in plasma
152 donors.

153 **Table 1. Baseline characteristics of donations**

	n	mean	median	SD	IQR
Age	12313	44,0	45,8	12,8	34,2-54,3
IgG	199	1066,9	1038,0	217,8	910-1185
IgA	199	236,6	224,0	100,9	162-292
IgM	199	113,0	100,0	64,3	69-138
Leukocyte	10105	7,4	7,2	1,8	6,1-8,5
Haemoglobin	11604	14,9	14,9	1,3	14-15,8
Haematocrit	11604	45,1	45,1	3,5	42,6-47,5
Platelets	11603	247,9	243,0	54,3	211-280

Neutrophil count	11603	4,4	4,2	1,4	3,4-5,2
Neutrophil %	11603	58,8	58,9	7,5	53,8-63,9
Lymphocyte count	11602	2,3	2,3	0,7	1,9-2,7
Lymphocyte %	11602	31,7	31,5	6,9	27-36,2
Monocyte count	11602	0,5	0,5	0,1	0,4-0,6
Monocyte%	11602	6,5	6,4	1,5	5,5-7,4
Eosinophil count	11603	0,2	0,2	0,1	0,1-0,2
Eosinophil %	11603	2,5	2,1	1,8	1,3-3,2
Basophil count	11603	0,0	0,0	0,0	0-0
Basophil %	11603	0,5	0,5	0,2	0,3-0,6

154

155 No differences in anti SARS-CoV2 reactivity due to sex, age or blood
156 group of donations were found (Table 2).

157 **Table 2. Sex, age range and blood group of positive/negative anti**
158 **SARS-COV2 donations analysed**

159

	Negative		Positive	
	n	%	n	%
Female	4531	38.1%	164	40.3%
Male	7375	61.9%	243	59.7%
<30	3551	29.8%	104	25.6%
30 to 45	5036	42.3%	180	44.2%
45 to 60	1151	9.7%	42	10.3%
60 to 75	2168	18.2%	81	19.9%


A	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
B	919	7.7%	22	5.4%
O	5151	43.3%	171	42.0%

160

161 Three 2019 donations were reactive (from July, September and October;
162 1,142 donations from year 2019 were analyzed) but none of them were
163 positive when testing separately IgG, IgA or IgM. Their ODs were 1.05,
164 1.08 and 5.46 respectively.

165 Seropositivity rate (positive donations x 100 / total analyzed donations per
166 week) grew up from week 11 to week 25, reaching a 11.1% peak, with just
167 subtle descents until week 43 when the second wave arose in our country.
168 Plateau was reached by the last week of May 2020, 11 weeks after close
169 lockdown in Spain and 17 weeks after 31/01, the date of the first declared
170 case in our country. 660 out of 9,886 single donors were positive within
171 weeks 11 to 43 (Fig 1). Seroprevalence was therefore 6.73% at the end of
172 the first

173 wave.



174

175 Fig 1. COVID-19 seropositive donation rate. 2020 evolution by weeks.

176

177

Immunoglobulin levels didn't show any differences as comparing positive and negative donations (Table 3). Haemoglobin (14.9 vs 14.7 g/dL; $p < 0.001$) and haematocrit (45.2% vs 44.4%; $p < 0.001$) were both significantly lower in positive donations. Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells* $10^3/\mu\text{L}$; $p = 0.026$). Trends were found of lower number of neutrophils (4.3 vs. 4.2 cells* $10^3/\mu\text{L}$; $p = 0.117$), lower count of monocytes (0.46 vs. 0.45 cells* $10^3/\mu\text{L}$; $p = 0.117$) and higher percent of basophils (0.49% vs 0.51%; $p = 0.131$) in positive donations as compared with negative ones.

Table 3. Descriptive analyses of age, immunoglobulins and haemogram of

reactive and non-reactive donations

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	45.8	12.8	34.2-54.2
	Positive	407	44.2	46.5	13.0	32.8-54.8
IgA	Negative	194	236.9	223.5	101.3	163-292
	Positive	5	224.4	274.0	92.3	134-282
IgG	Negative	194	1065.4	1037.5	217.4	910-1185
	Positive	5	1123.8	1095.0	249.9	924-1229
IgM	Negative	194	113.3	100.5	64.8	69-138
	Positive	5	103.0	89.0	41.7	78-97
WBC ^a	Negative	9759	7.4	7.2	1.8	6.13-8.49
	Positive	346	7.2	7.1	1.6	6.11-8.12
Hb ^b	Negative	11218	14.9	14.9	1.3	14-15.8
	Positive	386	14.7	14.7	1.2	13.8-15.4
Hematocrite ^b	Negative	11218	45.1	45.2	3.5	42.7-47.6
	Positive	386	44.5	44.4	3.5	42.3-46.6
Platelets	Negative	11217	247.9	243.0	54.3	211-280
	Positive	386	247.3	242.5	55.7	206-276
Neutrophil						
count ^c	Negative	11217	4.4	4.3	1.4	3.44-5.19
	Positive	386	4.3	4.2	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	58.9	7.5	53.8-63.9
	Positive	386	58.5	58.7	7.1	54.3-63.4

Lymphocyte						
count	Negative	11216	2.3	2.3	0.7	1.86-2.72
	Positive	386	2.3	2.2	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	31.5	6.9	27-36.2
	Positive	386	32.1	32.4	6.6	27.3-36.1
Monocyte						
count ^d	Negative	11216	0.5	0.46	0.1	0.38-0.56
	Positive	386	0.5	0.46	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	6.4	1.5	5.5-7.4
	Positive	386	6.5	6.4	1.4	5.5-7.3
Eosinophil						
count	Negative	11217	0.2	0.2	0.1	0.09-0.23
	Positive	386	0.2	0.1	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	2.1	1.8	1.3-3.2
	Positive	386	2.4	2.0	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	0.0	0.0	0.02-0.04
	Positive	386	0.0	0.0	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	0.5	0.2	0.3-0.6
	Positive	386	0.5	0.5	0.3	0.4-0.6

178 Units: Immunoglobulins (mg/dL); Hb (g/dL); haemogram counts

179 (cells*10³/μL)

180 ^a p=0.026

181 ^b p<0.001

182 ^c p=0.117

183 ^dp=0.131

184 As layering data by sex (Table 4), the fact arose that haematocrit (46.8%
 185 vs 45.9%; p<0.001) and haemoglobin (15.5 vs 15.3 g/dL; p<0.001) were
 186 significantly lower just in males and that positive females had significantly
 187 less WBC (7.67 vs 7.25 cells*10³/μL; p=0.027) and neutrophil numbers
 188 (4.53 vs 4.27 cells*10³/μL; p=0.014).

189 **Table 4. Descriptive analysis of age, age, immunoglobulins and**
 190 **haemogram of reactive and non-reactive donations layered by sex**

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	43.50	13.3	30.3-53.3
		Positive	164	42.1	45.39	13.6	28.6-53.1
	Male	Negative	7375	45.2	46.81	12.2	36.7-54.8
		Positive	243	45.7	46.98	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	200.00	97.0	157-250
		Positive	3	235.3	274.00	105.5	116-316
	Male	Negative	140	245.6	233.50	101.9	176.5-302.5
		Positive	2	208.0	208.00	104.7	134-282
IgG	Female	Negative	54	1076.4	1062.50	191.3	964-1186
		Positive	3	1082.7	1095.00	152.9	924-1229
	Male	Negative	140	1061.2	1029.00	227.2	903-1181.5
		Positive	2	1185.5	1185.50	436.3	877-1494
IgM	Female	Negative	54	143.1	129.50	64.6	94-169
		Positive	3	114.3	89.00	53.7	78-176
	Male	Negative	140	101.8	90.00	61.3	64.5-121

		Positive	2	86.0	86.00	15.6	75-97
Mean							
corpuscular							
volume	Female	Negative	3618	91.2	91.50	4.8	88.4-94.4
		Positive	142	91.2	91.40	4.1	88.9-93.5
	Male	Negative	6141	90.9	91.00	4.6	88.1-93.8
		Positive	204	90.6	91.00	4.8	88-94.1
WBC	Female ^a	Negative	3618	7.8	7.69	1.9	6.49-9
		Positive	142	7.4	7.21	1.5	6.27-8.26
	Male	Negative	6949	7.2	7.02	1.8	5.99-8.2
		Positive	229	7.1	6.98	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	13.80	0.9	13.2-14.4
		Positive	157	13.7	13.80	0.9	13.2-14.3
	Male ^b	Negative	6949	15.5	15.50	1.0	14.9-16.2
		Positive	229	15.3	15.30	1.0	14.7-15.8
Haematocrit	Female	Negative	4269	42.4	42.30	2.7	40.6-44
		Positive	157	42.1	42.00	2.5	40.5-43.6
	Male ^b	Negative	6949	46.8	46.80	2.8	45-48.6
		Positive	229	46.2	45.90	3.0	44.3-47.7
Platelets	Female ^c	Negative	4268	265.9	261.00	56.6	228-300
		Positive	157	261.0	255.00	60.5	219-296
	Male	Negative	6949	236.8	233.00	49.6	204-266
		Positive	229	237.9	234.00	50.2	203-266
Neutrophil							
count	Female	Negative	4268	4.7	4.53	1.4	3.65-5.47

		Positive	157	4.4	4.27	1.2	3.56-5.08
	Male	Negative	6949	4.3	4.10	1.4	3.34-4.95
		Positive	229	4.2	4.10	1.2	3.24-4.97
Neutrophil							
%	Female	Negative	4268	59.2	59.40	7.4	54.2-64.3
		Positive	157	58.1	58.10	7.2	54-62.9
	Male	Negative	6949	58.6	58.70	7.5	53.6-63.6
		Positive	229	58.8	58.70	7.0	54.6-63.5
Lymphocyte							
count	Female	Negative	4267	2.5	2.39	0.7	1.97-2.88
		Positive	157	2.4	2.35	0.6	2.02-2.81
	Male	Negative	6949	2.2	2.18	0.6	1.8-2.62
		Positive	229	2.2	2.17	0.6	1.8-2.51
Lymphocyte							
%	Female ^e	Negative	4267	32.0	31.70	6.9	27.4-36.5
		Positive	157	33.0	33.10	7.0	28.4-37
	Male	Negative	6949	31.5	31.30	6.9	26.8-36.1
		Positive	229	31.4	31.70	6.3	26.7-35.6
Monocyte							
count	Female ^f	Negative	4267	0.5	0.46	0.1	0.37-0.55
		Positive	157	0.5	0.44	0.1	0.36-0.52
	Male	Negative	6949	0.5	0.46	0.1	0.38-0.56
		Positive	229	0.5	0.47	0.1	0.38-0.55
Monocyte							
%	Female	Negative	4267	6.1	6.00	1.4	5.1-6.9

		Positive	157	6.1	6.00	1.4	5.2-6.9
	Male	Negative	6949	6.7	6.60	1.5	5.7-7.6
		Positive	229	6.7	6.70	1.4	5.8-7.6
Eosinophil							
count	Female	Negative	4268	0.2	0.14	0.1	0.09-0.21
		Positive	157	0.2	0.13	0.1	0.09-0.19
	Male	Negative	6949	0.2	0.16	0.1	0.1-0.24
		Positive	229	0.2	0.15	0.1	0.09-0.23
Eosinophil							
%	Female	Negative	4268	2.2	1.80	1.6	1.2-2.8
		Positive	157	2.3	1.80	1.7	1.1-2.8
	Male	Negative	6949	2.7	2.20	1.8	1.4-3.4
		Positive	229	2.5	2.10	1.7	1.4-3.2
Basophil							
count	Female	Negative	4268	0.0	0.03	0.0	0.02-0.05
		Positive	157	0.0	0.04	0.0	0.02-0.05
	Male	Negative	6949	0.0	0.03	0.0	0.02-0.04
		Positive	229	0.0	0.03	0.0	0.02-0.04
Basophil %	Female ^g	Negative	4268	0.5	0.40	0.2	0.3-0.6
		Positive	157	0.5	0.50	0.3	0.3-0.6
	Male	Negative	6949	0.5	0.50	0.2	0.3-0.6
		Positive	229	0.5	0.50	0.2	0.4-0.6

191 *p<0.05

192 Units:immunoglobulins (mg/dL); Hb(g/dL); haemogram counts

193 (cells*10³/μL) and percent

194 ^ap=0.027

195 ^bp<0.001

196 ^cp=0.152

197 ^dp=0.065

198 ^ep=0.074

199 ^fp=0.132

200 ^gp=0.060

201

202

203 Some trends were found as well related to sex. Regarding positive women
204 neutrophil percent would be lower (59.4% vs 58.10% p=0.065),
205 lymphocyte percent, higher (31.7% vs 33.10%; p=0.074), platelet count,
206 (261 vs 255 cells*10³/μL; p=0.152), monocyte count (0.46 vs 0.44
207 cells*10³/μL; p=0.132) and basophil percent (0.5% vs 0.4%; p=0.060)
208 lower. Anaemia was more frequent in positive male donors as (6.1% vs
209 9.6%; p=0.031). No other significant differences were found either in
210 males, females or overall (Fig 2).

211

	Overall	Male	Female
Hb	↓	↓	-
Hematocrite	↓	↓	-
Leukocyte count	↓	-	↓
Platelet count	-	-	↓
Neutrophil count	↓	-	↓
Neutrophil %	-	-	↑
Lymphocyte count	-	-	↓
Lymphocyte %	-	-	↓
Monocyte count	↓	-	↓
Basophil %	↑	-	↓

212 Fig 2. **Summary of haematological features in SARS-CoV-2 positive**
 213 **donations as compared to negative ones.** Intense-coloured arrows
 214 represent significant differences. Light-coloured arrows represent
 215 statistical trends.

216

217 Discussion

218 A similar seroprevalence to that reported in general population was found
 219 among blood donors without COVID-19 antecedents. The 6.73%
 220 seroprevalence is a little lower than that reported in the seroprevalence
 221 study ENE-COVID-19 promoted by the *Instituto Nacional de*
 222 *Epidemiología* [11], where it is reported that a 7.2% of the participants in
 223 our region would have anti SARS-CoV2 IgG antibodies by the end of June
 224 2020. Almost one quarter people in our region (25.51% according to
 225 National Institute of Statistics, INE 2020 data) is older than 65 and elderly
 226 are necessarily underrepresented in this study. That happens as well with

227 population aged under 18 (<4.5% in our region). One limitation of this
228 study is this of restricted age, but it would make just a little difference of
229 0.5% in seroprevalence estimation. Immunization rate would be a bit
230 higher regarding the fact that some individuals who do not exhibit
231 antibodies but still mount an efficient specific T-cell response [2]

232 Perhaps the main strength of our study is the large number of samples we
233 randomized and the long period we tested (15 months). The first recorded
234 COVID-19 case in Spain was reported on 31/01/2020, but three positive
235 donations were found as testing samples collected along 2019. That could
236 be meaningful in two opposite ways: one possible explanation would be
237 cross reactivity to seasonal cold coronaviruses and the other would be that
238 SARS-CoV-2 might have been circulating at least since 2019 summer.

239 It is now known that up to 28% people would have protection against
240 SARS-CoV-2 due to cross reaction to other coronaviruses [2]. It has been
241 checked that long-term cross-reactive both T-cells and antibodies can be
242 correlates of protection against COVID-19 [12]. Asymptomatic or mild
243 cases couldn't be diagnosed or reported before the first tests were
244 available. There are other reports about SARS-CoV-2 circulating in
245 Europe along 2019 [13]. Our three 2019 positive donors would be even
246 earlier cases, but the simplest explanation would be that of cross-
247 reactions. Some of the positives along the period of study might be as well
248 cross-reactive or both reactive due to SARS-CoV-2 infection together with
249 previous coronavirus immunity.

250 Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have
251 an influence on the probability to develop an asymptomatic COVID-19
252 infection in our cohort. Several smaller seroprevalence reports from
253 European countries support this feature [16-20]. Age and sex would not
254 therefore have a role in SARSCoV-2 infection susceptibility, but only in
255 their progression to severe forms.

256 Blood group has been reported elsewhere [7,21-23] to confere
257 susceptibility or determine severity of SARS-CoV2 infection. Most
258 published studies do not separate them. It should be noticed that there are
259 no large studies characterizing asymptomatic cases in literature, perhaps
260 this is one of the reports comprising one of the largest asymptomatic
261 cohorts to date. Relationship of ABO system with susceptibility is not
262 supported by our data. We excluded convalescent plasma donors,
263 opposite to other published studies, that focused into these asymptomatic
264 positive donors [22]. Perhaps blood group might play a role only in
265 symptomatic cases and would be therefore related to severity but not to
266 asymptomatic SARS-CoV-2 infection. Another surface antigens such as
267 HLA or KIR might be as well involved and should be studied.

268 Several blood count anomalies have been reported in SARS-CoV2
269 infection, notably lymphopenia and neutrophilia are related to the severest
270 forms [24]. Our data conversely reveal that asymptomatic positive women
271 had a significant lower count of WBC and neutrophils as compared to
272 negative ones. Similar low counts of WBC and neutrophils have been
273 reported in young (<19) cohorts, comprising mainly mild and asymptomatic

274 cases [25]. Perhaps this feature might be therefore a correlate of
275 mildness. Elevations of monocytes have been elsewhere reported in short
276 series of mild cases [26]. Our observation will be in the same line of those
277 findings but a gender bias cannot be discarded so far seropositive women
278 would go in the opposite direction.

279 Several reports about haemolytic anaemia secondary to SARSCoV-2 have
280 been published [27-30]. We cannot discard a mild silent haemolytic
281 anaemia in asymptomatic cases but just small asymptomatic cohorts are
282 published to date.

283 We can conclude that seroprevalence estimations through blood donation
284 analysis mirror population-based surveys. Sex and age would not affect
285 COVID-19 susceptibility but its severity. Gender differences are present
286 even in asymptomatic individuals: positive females have lower lymphocyte
287 counts whereas positive males, present anaemia more frequently than
288 negative ones. Further studies in large cohorts are needed to confirm
289 these gender differences and to characterize asymptomatic COVID-19
290 cases as they can help better understand immune response to COVID-19,
291 its pathogenesis and prognosis.

292

Acknowledgements

LB and MCM conceived and designed the study, NH, NO; MP and AP
acquired data, IP, AJ and MIGF performed analysis and interpretation of
laboratory data, MCM and LB drafted the article and revised it critically for

important intellectual content, all authors provided final approval of the version to be submitted.

The authors thank to all blood donors for making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and Roche for its support.

References

1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. *Clin Infect Dis*. 2020;72(2):254-256.
2. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID: PMC7427556.
3. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, et al. Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. *Vox Sang*. 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23. PMID: 33368373.
4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open*. 2021;4(1):e2033706.
5. Friston K, Costello A, Pillay D. 'Dark matter', second waves and epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978.
6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. *J Clin Invest*. 2021;131(2):e145545.
7. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilía J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. *Emerg Infect Dis*. 2021;27(1):113-21
8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res*. 2020;181:104880
9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol*. 2020;129:104480
10. Müller L, Ostermann PN, Walker A, Wienemann T, Mertens A, Adams O, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. *Eur J Clin Microbiol Infect Dis*. 2021 May;40(5):1063-1071. doi: 10.1007/s10096-021-04169-7. Epub 2021 Feb 3. PMID: 33534090; PMCID: PMC7856849.
11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*.

- 2020 Nov 27;371:m4509. doi: 10.1136/bmj.m4509. PMID: 33246972; PMCID: PMC7690290.
12. Poonia B, Kottlilil S. Immune Correlates of COVID-19 Control. *Front Immunol.* 2020;11:569611
 13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in emergency departments as a COVID-19 surveillance system: a time series study. *BMJ Open.* 2021;11(2):e044388.
 14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. *Immun Ageing.* 2020;17:22
 15. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making. *Immun Ageing.* 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w. PMID: 34016150; PMCID: PMC8134808.
 16. Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, et al. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. *Public Health.* 2021 Jan;190:132-134. doi: 10.1016/j.puhe.2020.11.014. Epub 2020 Nov 24. PMID: 33453689; PMCID: PMC7685039.
 17. Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health.* 2020 Nov;8(11):e1390-e1398. doi: 10.1016/S2214-109X(20)30387-9. Epub 2020 Sep 23. PMID: 32979314; PMCID: PMC7511212.
 18. Bogogiannidou Z, Speletas M, Vontas A, Nikoulis DJ, Dadouli K, Kyritsi MA, et al. Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020. *Vaccines (Basel).* 2021 May 13;9(5):504. doi: 10.3390/vaccines9050504. PMID: 34068100; PMCID: PMC8152765.
 19. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet.* 2020;396(10247):313-319
 20. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses.* 2021;13(2):160
 21. Muñoz-Díaz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. *Blood Transfus.* 2021 Jan;19(1):54-63. doi: 10.2450/2020.0256-20. Epub 2020 Nov 12. PMID: 33196417; PMCID: PMC7850930.

22. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group. *Infección y trombosis asociada a la COVID-19: posible papel del grupo sanguíneo ABO*. *Med Clin (Barc)*. 2020;155(8):340-343. doi:10.1016/j.medcli.2020.06.020
23. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. *Eur J Haematol*. 2020;105(5):540-546
24. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19 under 19: A meta-analysis. *Pediatr Pulmonol*. 2021 Jun;56(6):1332-1341. doi: 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606
25. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection. *Cytometry A*. 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020 Aug 14. PMID: 32654350; PMCID: PMC7404377
26. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M, et al. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report. *Ther Adv Hematol*. 2021 Apr 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID: 33995989; PMCID: PMC8082984.
27. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic Anemia Associated With Asymptomatic SARS-CoV-2 Infection. *Cureus*. 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918; PMCID: PMC8075761.
28. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ, et al. Evans syndrome and immune thrombocytopenia in two patients with COVID-19. *J Med Virol*. 2021 May;93(5):2642-2644. doi: 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID: PMC8013600.
29. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N, Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. *Leuk Lymphoma*. 2021 Feb 22:1-5. doi: 10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.
30. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. *Int J Biol Sci*. 2021 Jan 1;17(1):62-72
31. Dattilo M. The role of host defences in Covid 19 and treatments thereof. *Mol Med*. 2020;26(1):90

293

294

295

296

297 **Abbreviations**

298 Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M
299 (IgM); polymerase chain reaction (PCR); standard deviation (SD);
300 interquartile range (IQR); White blood cells (WBC), haemoglobin (Hb),
301 haematocrit (HCT)

302

303